Investigating how kindlin-3 affects neutrophil function in inflammation
Official title: Kindlin-3 signaling in neutrophils
Funded at Versiti Wisconsin, INC. · NIH-11013352 · Data updated 2026-11-12
This study is looking at how a protein called kindlin-3 helps white blood cells called neutrophils do their job better during inflammation, which could lead to new ways to treat ongoing inflammatory conditions while protecting healthy tissues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | March 1, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $411,992 |
| NIH project number | 5R01HL160861-04 |
| Project ID | NIH-11013352 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic inflammatory disorders or conditions involving neutrophil dysfunction.
✕Less likely to help
Patients with acute infections that do not involve neutrophil dysfunction may not benefit from this research.
What this research studies
This research focuses on understanding the role of kindlin-3 in neutrophils, which are key players in the body's immune response. It examines how kindlin-3 influences the recruitment of neutrophils to sites of inflammation and regulates their activity, including the production of reactive oxygen species and the formation of neutrophil extracellular traps. By exploring these mechanisms, the research aims to uncover how neutrophils can effectively combat infections while minimizing damage to healthy tissues. This could lead to new insights into managing chronic inflammatory disorders.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for chronic inflammatory conditions by targeting neutrophil function.
How similar studies have gone: Previous research has shown that targeting immune cell signaling pathways can lead to significant advancements in treating inflammatory diseases, suggesting potential success for this approach.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Ma, Yan-Qing — Versiti Wisconsin, INC.
- Study coordinator: Ma, Yan-Qing
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.